Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
4.6
Journals
Pharmaceuticals
Special Issues
Chemotherapeutic Agents
share announcement

Chemotherapeutic Agents

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (31 August 2015)

Special Issue Information

Dear Colleagues,

The journal “Pharmaceuticals” is planning to publish a special issue covering the topic “Chemotherapeutic Agents” and we are inviting you to contribute an article to this volume. Cancer survival has improved drastically in the last four decades. This is the culmination of many factors, most importantly endless work of scientists and clinicians to better understand the pathophysiology of neoplastic cells. Cancer is an extremely heterogeneous disease with several distinct clinical, pathological, genetic, and molecular features. Although significant advances have been accomplished to treat a few cancers such as chronic myelogenous leukemia (CML), acute promyelocytic leukemia (APL), testicular cancer and lymphomas, much more basic, translational and clinical research are needed to fight other hematologic and solid neoplasms. The novel chemotherapeutic agents have revolutionaized our ability to fight cancer. The design and mechanisms of action of the chemotherapeutic agents, their biological activity screening in vitro and in vivo, and subsequent clinical trials are ongoing need of modern industrialized societies. We would like you to share your contributions to the advances and opportunities in this burgeoning field of cancer chemotherapy drug discovery and development for this special issue. Areas of interest include basic and clinical research on novel:

  • Alkylating agents
  • Anti-metabolites
  • Plant alkaloids including vincas, taxanes, podophyllotoxins
  • Topoisomerase inhibitors
  • Kinase signaling pathways and inhibitors
  • Intracellular Redox Modification
  • Targeting Cancer Metabolic Pathways Modulators
  • Monoclonal Antibodies
  • Nanotechnology Drug Delivery
  • Modulators of Tumor Microenvironments
  • Metal- and Metalloid-based Chemotherapy Agents
  • Epigenetic Modifications

Dr. Ashkan Emadi & Dr. Dhimant Desai
Guest Editors

Submission

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed Open Access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 500 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.

 


Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

315 KiB  
Review
Glioblastoma Multiforme Therapy and Mechanisms of Resistance
by Yulian P. Ramirez, Jessica L. Weatherbee, Richard T. Wheelhouse and Alonzo H. Ross
Pharmaceuticals 2013, 6(12), 1475-1506; https://0-doi-org.brum.beds.ac.uk/10.3390/ph6121475 - 25 Nov 2013
Cited by 184 | Viewed by 16060
Abstract
Glioblastoma multiforme (GBM) is a grade IV brain tumor characterized by a heterogeneous population of cells that are highly infiltrative, angiogenic and resistant to chemotherapy. The current standard of care, comprised of surgical resection followed by radiation and the chemotherapeutic agent temozolomide, only [...] Read more.
Glioblastoma multiforme (GBM) is a grade IV brain tumor characterized by a heterogeneous population of cells that are highly infiltrative, angiogenic and resistant to chemotherapy. The current standard of care, comprised of surgical resection followed by radiation and the chemotherapeutic agent temozolomide, only provides patients with a 12–14 month survival period post-diagnosis. Long-term survival for GBM patients remains uncommon as cells with intrinsic or acquired resistance to treatment repopulate the tumor. In this review we will describe the mechanisms of resistance, and how they may be overcome to improve the survival of GBM patients by implementing novel chemotherapy drugs, new drug combinations and new approaches relating to DNA damage, angiogenesis and autophagy. Full article
(This article belongs to the Special Issue Chemotherapeutic Agents)
►▼ Show Figures

Figure 1

468 KiB  
Review
Nanoparticles as Drug Delivery Systems in Cancer Medicine: Emphasis on RNAi-Containing Nanoliposomes
by Mónica Rivera Díaz and Pablo E. Vivas-Mejia
Pharmaceuticals 2013, 6(11), 1361-1380; https://0-doi-org.brum.beds.ac.uk/10.3390/ph6111361 - 04 Nov 2013
Cited by 117 | Viewed by 12280
Abstract
Nanomedicine is a growing research field dealing with the creation and manipulation of materials at a nanometer scale for the better treatment, diagnosis and imaging of diseases. In cancer medicine, the use of nanoparticles as drug delivery systems has advanced the bioavailability, in [...] Read more.
Nanomedicine is a growing research field dealing with the creation and manipulation of materials at a nanometer scale for the better treatment, diagnosis and imaging of diseases. In cancer medicine, the use of nanoparticles as drug delivery systems has advanced the bioavailability, in vivo stability, intestinal absorption, solubility, sustained and targeted delivery, and therapeutic effectiveness of several anticancer agents. The expansion of novel nanoparticles for drug delivery is an exciting and challenging research filed, in particular for the delivery of emerging cancer therapies, including small interference RNA (siRNA) and microRNA (miRNAs)-based molecules. In this review, we focus on the currently available drug delivery systems for anticancer agents. In addition, we will discuss the promising use of nanoparticles for novel cancer treatment strategies. Full article
(This article belongs to the Special Issue Chemotherapeutic Agents)
►▼ Show Figures

Figure 1

1743 KiB  
Review
Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action
by Christina Leah B. Kline and Wafik S. El-Deiry
Pharmaceuticals 2013, 6(8), 988-1038; https://0-doi-org.brum.beds.ac.uk/10.3390/ph6080988 - 21 Aug 2013
Cited by 10 | Viewed by 16787
Abstract
The use of pharmaceuticals for colon cancer treatment has been increasingly personalized, in part due to the development of new molecular tools. In this review, we discuss the old and new colon cancer chemotherapeutics, and the parameters that have been shown to be [...] Read more.
The use of pharmaceuticals for colon cancer treatment has been increasingly personalized, in part due to the development of new molecular tools. In this review, we discuss the old and new colon cancer chemotherapeutics, and the parameters that have been shown to be predictive of efficacy and safety of these chemotherapeutics. In addition, we discuss how alternate pharmaceuticals have been developed in light of a potential lack of response or resistance to a particular chemotherapeutic. Full article
(This article belongs to the Special Issue Chemotherapeutic Agents)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop